DT2216 stands as a PROTAC-type protein degrader in clinical development. Its focal point is the degradation of the BCL-XL protein, an anti-apoptotic protein overexpressed in certain cancers, achieved through the Von Hippel-Lindau (VHL) E3 ligase. This development is geared towards potential antitumor activity.
Usually ships within 24 hours.